This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through November 3, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical: Archive
Tempus AI Boosts Its Clinical AI Capabilities Through Strategic Moves
by Sridatri Sarkar
TEM expands its clinical AI reach through regulatory wins, a new oncology partnership and a major digital-pathology acquisition.
MEDPositive Net Change HIMSNegative Net Change TEMNegative Net Change
medical
Reasons to Add Omnicell Stock to Your Portfolio Right Now
by Zacks Equity Research
OMCL's expanding SaaS pipeline, global push and solid solvency highlight growth potential despite rising competition.
CAHPositive Net Change OMCLNegative Net Change PAHCPositive Net Change BTSGPositive Net Change
medical
Do Options Traders Know Something About Owens & Minor Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Owens & Minor stock based on the movements in the options market lately.
OMIPositive Net Change
medical
The Zacks Analyst Blog Highlights HSBC, Abbott, Shell and Oak Valley
by Zacks Equity Research
HSBC, Abbott, Shell and Oak Valley feature in the latest Zacks Analyst Blog as analysts highlight operational resilience, strategic pivots and industry-specific challenges.
ABTPositive Net Change HSBCPositive Net Change OVLYPositive Net Change SHELNegative Net Change
finance medical oil-energy
Zacks.com featured highlights include Plains GP, Edison International, TD SYNNEX, CONMED and PG&E
by Zacks Equity Research
Plains GP, Edison International, TD SYNNEX, CONMED and PG&E stand out for value as low EV-to-EBITDA ratios spotlight potential opportunities.
EIXPositive Net Change PCGNegative Net Change CNMDPositive Net Change SNXPositive Net Change PAGPPositive Net Change
computers medical oil-energy utilities
Top Analyst Reports for HSBC, Abbott & Shell
by Mark Vickery
HSBC's Asia pivot, Abbott's device momentum and Shell's resilient Q3 results headline today's standout analyst reports.
EXCNegative Net Change ABTPositive Net Change PHMNegative Net Change HSBCPositive Net Change OVLYPositive Net Change UIPositive Net Change SHELNegative Net Change
finance medical oil-energy
Implied Volatility Surging for Eton Pharmaceuticals Stock Options
by Zacks Equity Research
Investors need to pay close attention to ETON stock based on the movements in the options market lately.
ETONPositive Net Change
medical
Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals
by Zacks Equity Research
PHVS shares jump as deucrictibant delivers rapid symptom relief in RAPIDe-3, boosting momentum toward a planned 2026 regulatory filing.
BCRXNegative Net Change IONSPositive Net Change KALVPositive Net Change PHVSPositive Net Change
biotechs medical
HIMS Stock Jumps After Buyout Deal, Boosts Blood Collection Efficiency
by Zacks Equity Research
Hims & Hers is set to acquire YourBio Health, adding bladeless microneedle tech to transform the blood collection experience.
ISRGNegative Net Change IDXXPositive Net Change HIMSNegative Net Change SOLVPositive Net Change
medical medical-devices
IDEXX Laboratories Stock Rallies 75.6% YTD: What's Behind the Surge?
by Zacks Equity Research
IDXX surges 75.6% YTD as strong CAG Diagnostics momentum and high-demand software solutions fuel growth.
BSXNegative Net Change MDTNegative Net Change IDXXPositive Net Change GMEDPositive Net Change
medical
HealthEquity Stock Gains as Q3 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
HQY stock gains post Q3 results as earnings and revenue top estimates, supported by rising HSAs and stronger margins.
BSXNegative Net Change ISRGNegative Net Change HQYPositive Net Change MEDPPositive Net Change
earnings medical medical-devices
GEHC and Mayo Clinic Launch GEMINI-RT to Aid Personalized Cancer Care
by Zacks Equity Research
GE HealthCare and Mayo Clinic unveil GEMINI-RT, which is likely to blend imaging, AI and monitoring to advance personalized cancer care.
BSXNegative Net Change ISRGNegative Net Change MEDPPositive Net Change GEHCPositive Net Change
medical medical-devices
ImmuCell's Two-Product Edge in Cattle Health Fuels Growth
by Urbashi Dutta
ICCC's innovative, antibiotic-free cattle health products drive margin recovery, real-world adoption and stock gains.
ICCCPositive Net Change
medical
BMY Gains on News of Continuation of Alzheimer's Disease Study
by Zacks Equity Research
Bristol Myers jumps after choosing to continue its phase III ADEPT-2 study on Cobenfy for Alzheimer-related psychosis, delaying data to next year.
BMYNegative Net Change FOLDPositive Net Change ANIPPositive Net Change CRMDPositive Net Change
biotechnology biotechs medical pharmaceuticals
Hologic's BCI Test Shows Growing Impact in Endocrine Therapy Decisions
by Moumi Mondal
HOLX's BCI test gains traction as new SABCS studies are set to highlight its growing role in guiding extended endocrine therapy decisions.
BDXPositive Net Change MDTNegative Net Change HOLXNo Net Change
medical medical-devices
Zoetis Stock Plummets 24.8% YTD: Here's What You Need to Know
by Zacks Equity Research
ZTS faces steep YTD losses as safety concerns hit key osteoarthritis therapies, forcing revenue cuts while new approvals aim to stabilize growth.
ZTSNegative Net Change CRMDPositive Net Change ADMAPositive Net Change ARQTNegative Net Change
biotechnology biotechs medical pharmaceuticals
Is the Options Market Predicting a Spike in AdaptHealth Stock?
by Zacks Equity Research
Investors need to pay close attention to AHCO stock based on the movements in the options market lately.
AHCONegative Net Change
medical
Here's Why You Should Add CONMED Stock to Your Portfolio Now
by Zacks Equity Research
CONMED gains momentum from high-margin platforms and supply-chain recovery, even as tariffs and dV5 adoption weigh on near-term margins.
CNMDPositive Net Change ISRGNegative Net Change IDXXPositive Net Change PODDNegative Net Change
medical medical-devices
Margins Face Tariff Pressure: Is ISRG's Profitability at Risk?
by Indrajit Bandyopadhyay
Intuitive Surgical's strong growth contrasts with tariff-driven margin pressure, raising questions about its ability to hold gross margins near 67%.
MDTNegative Net Change SYKNegative Net Change ISRGNegative Net Change
medical medical-devices
Should You Hold STERIS Stock in Your Portfolio for Now?
by Zacks Equity Research
STE posts solid AST and Healthcare growth, but currency swings and macro pressures pose rising challenges.
BSXNegative Net Change MDTNegative Net Change STENegative Net Change GMEDPositive Net Change
medical
5 Value Stocks With Exciting EV-to-EBITDA Ratios to Scoop Up
by Anindya Barman
PAGP, EIX, SNX, CNMD and PCG stand out with attractive EV-to-EBITDA ratios and strong earnings outlooks.
EIXPositive Net Change PCGNegative Net Change CNMDPositive Net Change SNXPositive Net Change PAGPPositive Net Change
computers medical oil-energy utilities
How Strong Is AbbVie's Immunology Franchise After Humira's LOE?
by Sundeep Ganoria
ABBV rebounds after Humira's LOE as soaring Skyrizi and Rinvoq sales drive a powerful immunology comeback.
JNJPositive Net Change LLYPositive Net Change ABBVNegative Net Change
biotechs medical pharmaceuticals
Zacks.com featured highlights include Phibro Animal Health, Argan and Ubiquiti
by Zacks Equity Research
PAHC, AGX and UI make Zacks' momentum screen as strong one-year gains meet brief pullbacks in a volatile market backdrop.
AGXPositive Net Change PAHCPositive Net Change UIPositive Net Change
communications computers medical
Ensign Group Expands Foothold in Three U.S. States With Facility Buyouts
by Zacks Equity Research
ENSG adds four skilled nursing facilities across Colorado, Arizona and Kansas, pushing its total healthcare operations to 373 nationwide.
ISRGNegative Net Change ANIPPositive Net Change ENSGPositive Net Change COLLNegative Net Change
medical
TLRY Stock Loses 38% in a Month: Should You Buy the Dip?
by Sundeep Ganoria
Tilray's slump deepens as a tighter U.S. hemp rule and a reverse split stir uncertainty despite gains in global cannabis sales.
CGCNegative Net Change TLRYPositive Net Change CURLFPositive Net Change
marijuana medical